JP2023535405A - 呼吸器疾患に関連する状態の処置および防止 - Google Patents
呼吸器疾患に関連する状態の処置および防止 Download PDFInfo
- Publication number
- JP2023535405A JP2023535405A JP2023504251A JP2023504251A JP2023535405A JP 2023535405 A JP2023535405 A JP 2023535405A JP 2023504251 A JP2023504251 A JP 2023504251A JP 2023504251 A JP2023504251 A JP 2023504251A JP 2023535405 A JP2023535405 A JP 2023535405A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- disease
- antigen
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055165P | 2020-07-22 | 2020-07-22 | |
| US63/055,165 | 2020-07-22 | ||
| US202063060503P | 2020-08-03 | 2020-08-03 | |
| US63/060,503 | 2020-08-03 | ||
| US202063108980P | 2020-11-03 | 2020-11-03 | |
| US63/108,980 | 2020-11-03 | ||
| PCT/US2021/042684 WO2022020542A1 (en) | 2020-07-22 | 2021-07-22 | Treatment and prevention of conditions associated with respiratory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535405A true JP2023535405A (ja) | 2023-08-17 |
| JP2023535405A5 JP2023535405A5 (cg-RX-API-DMAC10.html) | 2025-04-17 |
Family
ID=79729865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504251A Pending JP2023535405A (ja) | 2020-07-22 | 2021-07-22 | 呼吸器疾患に関連する状態の処置および防止 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230270845A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4185272A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023535405A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3186799A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022020542A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025504814A (ja) * | 2022-01-21 | 2025-02-19 | ユニバーシティー オブ ヒューストン システム | 呼吸器疾患のための経鼻ワクチンおよび治療剤 |
| CN114712304B (zh) * | 2022-04-18 | 2024-03-12 | 深圳大学 | 海藻酸钠基复合水凝胶的制备方法 |
| WO2025194158A1 (en) * | 2024-03-15 | 2025-09-18 | University Of Houston System | Mucosal vaccines against respiratory syncytial virus |
| WO2025199149A1 (en) * | 2024-03-18 | 2025-09-25 | Cour Pharmaceuticals Development Company Inc. | Sting agonism for antigen specific tolerance |
| CN120459057B (zh) * | 2025-06-06 | 2026-04-14 | 上海大学 | 一种单核细胞搭载型产氧脂质体及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019518739A (ja) * | 2016-05-16 | 2019-07-04 | インフェクシャス ディズィーズ リサーチ インスティチュート | Peg化リポソームおよび使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| EP3471778A4 (en) * | 2016-06-20 | 2020-02-19 | The Regents of The University of Michigan | COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES |
| KR101982710B1 (ko) * | 2017-03-17 | 2019-05-28 | 주식회사 큐라티스 | 스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물 |
| TW202003032A (zh) * | 2018-03-23 | 2020-01-16 | 美商科迪亞克生物科學公司 | 包含s t i n g 促效劑之胞外囊泡 |
-
2021
- 2021-07-22 JP JP2023504251A patent/JP2023535405A/ja active Pending
- 2021-07-22 US US18/017,659 patent/US20230270845A1/en active Pending
- 2021-07-22 CA CA3186799A patent/CA3186799A1/en active Pending
- 2021-07-22 EP EP21847219.9A patent/EP4185272A4/en active Pending
- 2021-07-22 WO PCT/US2021/042684 patent/WO2022020542A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019518739A (ja) * | 2016-05-16 | 2019-07-04 | インフェクシャス ディズィーズ リサーチ インスティチュート | Peg化リポソームおよび使用方法 |
Non-Patent Citations (3)
| Title |
|---|
| "Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2", BIORXIV, JPN6025034859, 23 July 2020 (2020-07-23), ISSN: 0005670459 * |
| THER ADV VACCINES, vol. 1(4), JPN6025034860, 2013, pages 131 - 143, ISSN: 0005670458 * |
| VIRUSES, vol. 12, 254, JPN6025034861, 25 February 2020 (2020-02-25), pages 1 - 15, ISSN: 0005670457 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3186799A1 (en) | 2022-01-27 |
| US20230270845A1 (en) | 2023-08-31 |
| EP4185272A4 (en) | 2025-01-22 |
| EP4185272A1 (en) | 2023-05-31 |
| WO2022020542A1 (en) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250127879A1 (en) | Newcastle disease viruses and uses thereof | |
| Alameh et al. | Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses | |
| Li et al. | Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine | |
| An et al. | Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2 | |
| US20230270845A1 (en) | Treatment and prevention of conditions associated with respiratory diseases | |
| US8809290B2 (en) | Methods and compositions to generate and control the effector profile of T cells by simultaneous loading and activation of selected subsets of antigen presenting cells | |
| US20180256655A1 (en) | Newcastle Disease Viruses and Uses Thereof | |
| Lee et al. | A booster dose of Delta× Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants | |
| Cao et al. | Inside-out assembly of viral antigens for the enhanced vaccination | |
| Wang et al. | IL-7 promotes mRNA vaccine-induced long-term immunity | |
| Verma et al. | Tailoring Tfh profiles enhances antibody persistence to a clade C HIV-1 vaccine in rhesus macaques | |
| Giovannoni et al. | Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy | |
| US20250195638A1 (en) | Treatment and prevention of conditions associated with respiratory diseases | |
| Wen et al. | A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2 | |
| Mathew et al. | Nasal CD4+ tissue-resident memory T cells provide cross-protective immunity to influenza | |
| JP7655566B2 (ja) | シンドビスウイルスベクター及びアゴニストモノクローナル抗体を用いる腫瘍免疫療法 | |
| US20230233674A1 (en) | Intranasal vaccines and therapeutics for respiratory diseases | |
| Gorman et al. | Collaboration between the Fab and Fc Contribute to Maximal Protection Against SARS-CoV-2 Following NVX-CoV2373 Subunit Vaccine with Matrix-M™ Vaccination | |
| Qi¹ et al. | Single-cell analysis of the adaptive immune response | |
| Chen et al. | Immunogenicity, Efficacy and Twelve-Month Storage Stability Studies of a Lyophilized Rabies mRNA Vaccine. Vaccines 2025, 13, 743 | |
| Fu et al. | IL-7 promotes mRNA vaccine-induced long-term immunity | |
| Slamanig | Development of an intranasal SARS-CoV-2 vaccine | |
| Abraş | Assessment of Immune Potency of SARS-CoV-2 VLP Vaccine in Mice, Enhanced Through Different Adjuvants and Liposome Complexation | |
| Davis-Porada | Human Immune Memory to COVID-19 mRNA Vaccines | |
| Daccache | Stem-like CD8 T Cells are Essential for Cellular Immunity but Restrain Antibody Responses During Influenza Infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240719 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240719 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251022 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260224 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260525 |